On the other hand, present data on the retina, combined with the results of the BENEDICT Phase 1 study showing that, in patients with type 2 diabetes and normal urinary albumin excretion, verapamil therapy failed to prevent microalbuminuria [3], confirm that this drug has no specific protective effects against microvascular disease of type 2 diabetes. This evidence concerns the gene ALB and type 2 diabetes mellitus.